Notice of GM

RNS Number : 2725C
ValiRx PLC
27 June 2016
 

 

 

ValiRx Plc

("ValiRx" or the "Company")

Shareholder Circular and Notice of General Meeting

 

London, UK. 27th June 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that it has today published and posted to shareholders a circular in relation to a forthcoming General Meeting, due to be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN at 11:30 a.m. on 12th July 2016.

 

The directors will propose at the General Meeting a shareholder resolution seeking consent for the dis-application of pre-emptive rights.

 

A copy of the Circular is available on the Company's website.

 

*** ENDS ***

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

tarquin.edwards@valirx.com

Mark Treharne, Corporate Development Manager

Tel: +44 (0) 7736 564 686

mark.treharne@valirx.com



Cairn Financial Advisers LLP (Nominated Adviser)

Tel: +44 (0) 20 7148 7900

Liam Murray / Richard Nash




Northland Capital Partners Limited (Broker)

Tel: +44 (0) 20 7382 1100

Patrick Claridge / David Hignell (Corporate Finance)

John Howes / Abigail Wayne (Broking)


 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOGAKQDKOBKDQAB

Companies

Valirx (VAL)
UK 100

Latest directors dealings